Proscia has unveiled its latest breakthrough in artificial intelligence-enabled pathology with the launch of Concentriq Embeddings and the Proscia AI Toolkit, marking a significant advancement in precision medicine research and development.
The new Concentriq Embeddings platform delivers a sophisticated collection of pathology foundation models, leveraging Proscia's extensive proprietary datasets to empower AI developers and researchers in their routine workflows. The technology has demonstrated remarkable efficiency improvements during pilot testing, with one notable internal case study showing data scientists achieving a 13-fold increase in development speed, successfully generating 80 AI-based breast cancer biomarker prediction models in less than 24 hours.
Advanced Technical Capabilities
The platform operates within Proscia's Concentriq ecosystem, enabling pathology and data science teams to generate high-dimensional numerical representations, or "embeddings," from whole slide images. The system initially incorporates four foundation models - DINOv2, PLIP, ConvNext, and CTransPath - with plans for continuous expansion as new models emerge.
Researchers can select optimal foundation models tailored to their specific requirements, supporting various applications including:
- Image classification and segmentation
- Risk scoring
- Multimodal data integration
- Rapid prototyping
- Large-scale AI model development
Enhanced Research Capabilities
The platform's capabilities are further strengthened by Proscia's real-world data (RWD) offering, providing researchers access to high-quality, diverse multimodal datasets. This comprehensive data access enables the development of more accurate and clinically viable AI models.
"It's an exciting time at the intersection of medicine and technology," stated David West, Proscia's CEO. "The proliferation of digital pathology and explosion in capabilities of today's AI models bring a totally new scale to how to develop therapies and diagnose patients. We're approaching a world where experiments that once took years can now be run in silico in a matter of days."
Accelerating Innovation in Pathology
To complement Concentriq Embeddings, Proscia has also introduced the Proscia AI Toolkit, an open-source resource suite designed to accelerate AI adoption throughout the life sciences community.
Julianna Ianni, VP of AI research & development at Proscia, emphasized the transformative potential of the technology: "Concentriq Embeddings will spark a new wave of innovation in pathology, setting the stage for transformative advancements in both research and patient care."
The launch represents a significant step forward in the practical application of AI in pathology, moving beyond theoretical potential to deliver tangible improvements in research efficiency and capabilities. As the platform continues to evolve and expand its model offerings, it promises to further accelerate the development of precision medicine applications and enhance pathology research workflows.
